PRESS

Munich, March 3, 2025 – Cardiogen GmbH, a preclinical clinical life science company focusing on cardiovascular regeneration and cellular reprogramming, announced first closings of its Seed financing round. Closing of Seed Round This financing and closings include new undisclosed investors. The current proceeds will be used to complete the preclinical development for Cardiogen’s lead therapeutic candidate, CGN 001 , which is being developed for the treatment of acute myocardia

Munich, January 13, 2025 - Cardiogen GmbH, a preclinical clinical life science company focusing on cardiovascular regeneration and...